Vicuron's Dalbavancin User Fee Date Extended To Sept. 21
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA extends user fee deadline for the lipoglycopeptide antibiotic by three months to review additional chemistry, manufacturing & controls data. Vicuron plans to amend the NDA for its antifungal anidulafungin in the second quarter.